Here’s a sneak peek of screens you’ll find in the AHFS Clinical Drug Information app that’s currently in the final development stages. Check back as progress continues!
The May update to the AHFS Patient Medication Information (PMI) database has been published. Highlights of the update include:
New PMI Monographs:
- Amphotericin B Liposomal Injection (AmBisome®)
- Amphotericin B liposomal injection is used to treat fungal infections such as cryptococcal meningitis and visceral leishmaniasis
- Dexamethasone Injection (Decadron® & Available generically)
- Dexamethasone injection is used to treat severe allergic reactions, certain types of edema, gastrointestinal disease, and certain types of arthritis, and other diseases treated by corticosteroids
- Reslizumab Injection (Cinqair®)
- Reslizumab injection is used along with other medications to treat asthma
FDA MedWatch Alerts – Monograph Revisions
- Warning regarding compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported
- Ticagrelor and Vortioxetine
- Brand name change for vortioxetine (Brintellix) due to name confusion with ticagrelor (Brilinta)
- Olanzapine and Olanzapine injection
- Rare, but serious skin reactions
- Serious adverse effects generally outweigh benefits for patients with sinusitis, bronchitis, and uncomplicated UTIs
- Affected monographs:
- Ciprofloxacin, ciprofloxacin injection, gemifloxacin, levofloxacin, levofloxacin injection, moxifloxacin, moxifloxacin injection, ofloxacin
If you’re attending MLA: Mosaic 16, May 13th – 18th in Toronto, visit the ASHP booth, #726, and get an exclusive preview of AHFS Clinical Drug Information, the next big thing for easy access to real-time drug information and updates.
Sign up for more information about AHFS Clinical Drug Information and other ASHP products for institutions, and register for a chance to win a Fitbit Charge HR!